Fedratinib and Tracleer (Bosentan Tablets for Oral Suspension)

In the database of official manuals used in the service creation an interaction registered by statistical results of studies was found, which can either lead to negative consequences for the patient health or strengthen a mutual positive effect. A doctor should be consulted to address the issue of joint drug administration.

Consumer information for this interaction is not currently available.GENERALLY AVOID: Coadministration with potent or moderate inducers of CYP450 3A4 may decrease the plasma concentrations of fedratinib, which is a substrate of the isoenzyme. However, clinical data evaluating this interaction are not available. MANAGEMENT: According to the product labeling, concomitant use of fedratinib with potent or moderate CYP450 3A4 inducers should be avoided. References "Product Information. Inrebic (fedratinib)." Celgene Corporation, Summit, NJ.

GENERALLY AVOID: Coadministration with potent or moderate inducers of CYP450 3A4 may decrease the plasma concentrations of fedratinib, which is a substrate of the isoenzyme. However, clinical data evaluating this interaction are not available.

MANAGEMENT: According to the product labeling, concomitant use of fedratinib with potent or moderate CYP450 3A4 inducers should be avoided.

Fedratinib

Generic Name: fedratinib

Brand name: Inrebic

Synonyms: n.a.

What is Fedratinib?

Tracleer (Bosentan Tablets for Oral Suspension)

Generic Name: bosentan

Brand name: Tracleer

Synonyms: Tracleer

What is Tracleer (Bosentan Tablets for Oral Suspension)?